Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Inc. is a specific US-listed biopharmaceutical franchise built on RNA-interference therapeutics — Amvuttra and Onpattro as the TTR-amyloidosis franchise plus a pipeline of RNAi programs. Up 5% today but down 49% year to date and 48% over 12 months, sitting at just the 3rd percentile of the 52-week range on a breaking-down tape.

Where it stands after Q2:

• The Q2 print was a specific disappointment: shares fell ~28% on the print with FY26 guidance cut on softer-than-expected TTR sales (Amvuttra/Onpattro). Roughly $13B of equity value erased in a single day, with ARWR catching up in market cap — the specific pattern of a franchise where the leading-therapy-franchise assumption has cracked.
• The valuation reflects the reset: TTM P/E of 69 versus forward P/E of 31 on FY26 EPS estimates of $6.91 rising to FY27 estimates of $9.85 — implying forward P/E of 22 on the FY27 base. Price-to-sales of 9.3 remains elevated relative to the growth path management now guides.
• The bear framing is specific and repeated: bears note this is a recurring embarrassment for the CEO with a $200M cut tied to 2L demand normalization — the specific pattern of a management team that has now missed the same demand-modeling exercise multiple times, which is what compounds the credibility damage.
• The counterweight is a specific dated catalyst: bulls quietly frame the ALN-HTT02 HD data at EHDN on Oct 23 as the next possible pivot — the specific readout that could reset the pipeline narrative independent of the TTR-franchise reset. Securities-fraud investigations from multiple plaintiffs firms add specific legal overhang.

Oct 23 EHDN needs positive ALN-HTT02 HD data plus dated commentary on TTR-franchise stabilization to arrest the breaking-down tape; another quarter of TTR walk-back plus adverse ALN-HTT02 data would take the stock through the 3%-of-range low — the specific risk for a franchise where the whole tape has priced significant reset.